Liproca Depot is NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug that binds and blocks androgen receptors. Prostate cancer patients are commonly treated with a combination of different anti-androgen drugs. The purpose of this treatment is to decrease the size of the tumor and prostate before more radical and interventional treatments including radiation and surgery. Drugs are given systemically and cause severe side effects, such as gynecomastia and breast pain, anemia, increase in body fat and loss of libido and erectile dysfunction, which all have a substantial impact on the quality of life. A local treatment directly into the prostate adjacent to the tumor, avoiding systemic exposure therefore has a clear medical benefit.. Liproca Depot is LIDDS’ first project in development and also the most advanced. The product has been investigated in close to 160 patients in several clinical studies. The data generated indicates a controlled and sustained local release for up to six months after a single administration into the prostate. Furthermore, the treatment has been shown to be tolerable and safe with observed clinically beneficial effects on tumor tissue, prostate volume and the prostate-specific antigen PSA. Liproca Depot is being prepared for a clinical phase III study including a regulatory validation by the EMA on the preclinical data package and phase III study protocol, an upgrading of the manufacturing process for phase III and extensive business development activities to secure financing of the phase III study.